NCT07403370Completed
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Olanzapine 2.5 mg Versus 5 mg Versus 10 mg in Highly Emetogenic Regimens: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2493 (actual)
- First submitted
- 18 Jan 2026
- Start date
- 18 Jan 2026
- Primary completion date
- 15 Feb 2026
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Diseases
- Childhood cancers
- NCT number
- NCT07403370
What you commit to
- Study type: Observational
- Participants enrolled: 2493
- From 18 Jan 2026 to the primary completion date, 15 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Studies where olanzapine is used as rescue medication only. Studies with overlapping patient populations (the most recent or complete publication will be selected).
Other
- Non-solid tumors patients, non-randomized studies, observational studies, case reports, reviews.
- Studies involving pediatric populations, non-HEC regimens.
Who the study is looking for
- Olanzapine was used to prevent nausea and vomiting (HER-INV) in solid tumors patients receiving highly emetogenic regimens.
- Randomized controlled trials (RCTs), including conference abstracts if sufficient data are provided.
- Adult patients (≥18 years) with solid tumors receiving highly emetogenic chemotherapy (HEC).
- 3\. Olanzapine at 2.5 mg, 5 mg, or 10 mg, added to a standard triple antiemetic regimen (NK1 receptor antagonist + 5-HT3 receptor antagonist + dexamethasone).
- 4\. Any of the other three olanzapine doses or placebo (2.5 mg vs. 5 mg vs. 10 mg, or vs. placebo).
- 5\. At least one of the pre-specified efficacy or safety outcomes must be reported.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medical Oncology Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.